Preventing the rise in obesity-related cancers in Asia
Long-term multisectoral preventive actions that take into account local requirements are needed
Immunotherapy combinations consolidate their place in the first-line treatment of unresectable hepatocellular carcinoma
Promising new data are presented for nivolumab plus ipilimumab and the single tremelimumab regular interval durvalumab regimen in Asian patients and those with impaired liver function
Studies show two promising new immune-related targets in cancer
Agents targeting B7-H3 and CEACAM6 pass their initial clinical tests, according to results from first-in-human trials
Short durvalumab infusions appear to be safe for the first-line treatment of advanced biliary tract cancer
Early results from a phase III trial support 30-minutes infusions of immunotherapy with some advantages for patients
Two oral immune checkpoint inhibitors show preliminary efficacy and manageable safety in early trials
Promising results support the further development of new small-molecule PD-L1 inhibitors with favourable benefit–risk profiles and improved ease of use compared with antibodies
Education sets the basis for an AI-driven future of oncology
The deployment of artificial intelligence could lead to substantial advances in cancer care, but collaborative efforts are needed to increase trust among end users
Cancer Control Principles
Redispensing cancer medicines means caring for the environment
Some initiatives show that collection and distribution of unused medicines can help tackle drug waste, with a potential impact on emissions associated to oncology therapies
Translating cancer genome insights into practical clinical tools
Findings from complex statistical modelling can form the basis for easy-to-use precision diagnostic and risk-stratification tools to help inform management decisions
Studies present a wider application of sequencing techniques for the treatment of cancer
Whole-genome sequencing and single-cell sequencing can provide valuable insights not only in the identification of new therapy targets, but also to assess minimal residual disease and overcome treatment resistance
Liquid biopsies are quickly evolving beyond ctDNA, but technical challenges remain
Newly-presented studies highlight that insights into cancer can also be unlocked from circulating tumour cells, exosomal microRNA and cell-free RNA